1349 |
Drug-eluting Balloon or Stent: How Will It Shift Paradigm in BTK Lesions ? |
Andrej Schmidt |
May. 11. 12 |
1348 |
ACTIVE Study: Co-Cr Balloon Expandable Stent : What Advantages over Standard Self-expandable Stent ? |
William A. Gray |
May. 11. 12 |
1347 |
Is There a Default "Gold Standard" in the Lower Limb for Revascularization? |
Lawrence A. Garcia |
May. 11. 12 |
1346 |
Drug-eluting Balloon or Stent in Femoropopliteal Lesions: How Far We Are ? |
Mark W. Burket |
May. 11. 12 |
1345 |
Step-wise Approach of Ilio-femoral CTO Lesions: Antegrade or Retrograde |
Andrej Schmidt |
May. 11. 12 |
1344 |
TAVI Update 2012: The Year in Review |
Martin Bert Leon |
May. 11. 12 |
1343 |
When Is TAVI Not Cost-effective? |
David Joel Cohen |
May. 11. 12 |
1342 |
TAVI for Aortic Regurgitation and Complex Valvular Heart Disease |
Bernard R. Chevalier |
May. 11. 12 |
1341 |
Valve-in-Valve TAVI |
Eberhard Grube |
May. 11. 12 |
1340 |
Conduction Disturbance: Prevalence and Prevention |
Ian T. Meredith |
May. 11. 12 |